The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Schein Pharmaceutical
Approval Status: Approved December 1997
Treatment for: anti-inflammatory
General Information
Ketoprofen, the generic equivalent of Wyeth Ayerst's Oruvail, has received approval as a non-steroidal anti-inflammatory. Ketoprofen will be available in 200 mg extended release capsules.